Member Info for 5085

Listen to the gasps when 94% was referenced

https://twitter.com/OxBioDynamics/status/1669730142485200897

Not mentioned in the latest release

Phillip Pierorazio, Section Chief of Urology at Penn Presbyterian Medical Center and Professor of Surgery at the Hospital of the University of Pennsylvania, hopes the PSE test will have an immediate impact.

"Although the traditional PSA has demonstrated clinical utility in prostate cancer screening and monitoring, it also has limitations that are well-described," Pierorzio said in a release. "A more sensitive and specific test would have the potential to increase diagnostic accuracy and address some of the current challenges with prostate cancer screening."

https://healthnews.com/news/device-limit-prostate-cancer-overdiagnosis/

Wrong board lol

Phillip Pierorazio, Section Chief of Urology at Penn Presbyterian Medical Center and Professor of Surgery at the Hospital of the University of Pennsylvania, hopes the PSE test will have an immediate impact.

"Although the traditional PSA has demonstrated clinical utility in prostate cancer screening and monitoring, it also has limitations that are well-described," Pierorzio said in a release. "A more sensitive and specific test would have the potential to increase diagnostic accuracy and address some of the current challenges with prostate cancer screening."

https://healthnews.com/news/device-limit-prostate-cancer-overdiagnosis/

It will go soon, in a big way

I don’t see a takeover but I do see a massive, long term, licensing agreement with one of the majors.

Lincolnite

I only see 100% because fear of litigation, patient care, why would anyone (now the news is out there) do a PSA test in isolation?

Krull, not sure what the current numbers are but 13 years ago the US spent $3 billion a year on PSA tests.

The way I look at it now, why would anyone have a PSA test in isolation, the results are just not accurate enough.

When the doors blow off this one, people are going to be staggered, to say the least.

Https://prostatecanceruk.org/about-us/news-and-views/2023/02/can-this-new-blood-test-diagnose-prostate-cancer-with-94-accuracy

Clear to see the post, now removed, was simply a fake.

You have to laugh at the stupidity and desperation of some people.

Https://cancerworld.net/new-prostate-cancer-blood-test-psa-epigenetic/

Slacker you dough-nut look at the date of the article......................lolololol

This is an interesting study https://alsnewstoday.com/news/biomarkers-may-help-determine-als-progression-edaravone-response/ and the sponsor is no small entity

Https://www.nytimes.com/2010/03/10/opinion/10Ablin.html

This quarter the American Medical Association only issued 19 new codes

Links at the bottom of this page https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes#:~:text=PLA%20test%20codes%20will%20be,the%20quarter%20following%20their%20publication.

The bottom one provides the most information

INTRODUCTION AND OBJECTIVES: Current diagnostic bloodtests for prostate cancer (PCa) are unreliable for the early stage dis-ease, resulting in numerous unnecessary prostate biopsies in men withbenign disease and false reassurance of negative biopsies in men withprostate cancer. In comparison to the imaging biomarker MRI, whichidentifies established and significant prostate cancer we investigateearly epigenetic changes as a diagnostic biomarker. Three-dimensionalgenome architecture and chromosome structures undergo changesearly during tumourigenesis both in tumour and in circulating cells andcan be potentially used for cancer diagnosis.METHODS: In this report, we have performed chromosomeconformation screening for 14,240 chromosomal loops in the loci of 425cancer related genes in peripheral blood mononuclear cells (PBMCs) ofn¼107 PCa patients and n¼105 non-cancer controls. The cancercohort consisted of all D'Amico risk groups including metastaticdisease.RESULTS: Our data show that PBMCs from PCa patients ac-quire specific chromosome conformation changes in the loci of cancer-related genes. New chromosomal loops in the loci of CASP2, ETS1,SLC22A3, MAP3K14 genes were unique to the PCa cohort. Similarchromosomal conformations were identified in primary prostate tumoursfrom these patients, but not in normal prostate tissues. Blind testing on avalidation cohort of n¼10 pts and n¼10 controls yielded PCa detectionwith 80% sensitivity and 80% specificity. Surprisingly, utilising thesignature to predict D'Amico low risk v high risk disease was also highlyaccurate (Sensitivity 84%, Specificity 89%).CONCLUSIONS: We have identified a subset of blood chro-mosomal conformations that are strongly indicative of PCa presenceand possibly risk of advanced disease. These signatures have a sig-nificant potential for development of a quick diagnostic blood test forprostate cancer or as staging adjunct

https://www.researchgate.net/publication/324205403_MP35-13_WHITE_BLOOD_CELLS_FROM_PROSTATE_CANCER_PATIENTS_CARRY_DISTINCT_CHROMOSOME_CONFORMATIONS

Routinely screening all men to check their prostate-specific antigen (PSA) levels is a controversial subject in the international medical community. There are several reasons for this.

PSA tests are unreliable and can suggest prostate cancer when no cancer exists (a false-positive result). Most men are now offered an MRI scan before a biopsy to help avoid unnecessary tests, but some men may have invasive, and sometimes painful, biopsies for no reason.

Furthermore, around 1 in 7 of those with normal PSA levels may have prostate cancer (a false-negative result), so many cases may be missed.

The PSA test can find aggressive prostate cancer that needs treatment, but it can also find slow-growing cancer that may never cause symptoms or shorten life. Some men may face difficult decisions about treatment, although this is less likely now that most men are offered an MRI scan before further tests and treatment

Treating prostate cancer in its early stages can be beneficial in some cases, but the side effects of the various treatments are potentially so serious that men may choose to delay treatment until it's absolutely necessary.

https://www.nhs.uk/conditions/prostate-cancer/psa-testing/

Scientists have developed a more accurate, minimally invasive, and inexpensive diagnostic tool for detecting prostate cancer in its early stages. The Prostate Screening EpiSwitch (PSE) blood test has shown remarkable accuracy of 94%, beating the widely used prostate-specific antigen (PSA) blood test that is highly unreliable and only indicates the need for further investigations.

https://oncologycompass.ch/blog/post/game-changer-in-prostate-cancer-detection

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most patients do not die from the disease. Prostate specific antigen (PSA), the most widely used oncologic biomarker, has revolutionized screening and early detection, resulting in reduced proportion of patients presenting with advanced disease. However, given the inherent limitations of PSA, additional diagnostic and prognostic tools are needed to facilitate early detection and accurate risk stratification of disease. Serum, urine, and tissue-based biomarkers are increasingly being incorporated into the clinical care paradigm, but there is still a limited understanding of how to use them most effectively

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201356/

It took the company 10 years to get this product on the start line, have some patience, all will come good.